BOKF vs GGAL

BOKF exhibits weak financial health with a Piotroski F-Score of just 2/9, signaling significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows strong recent earnings growth (YoY EPS +17%, Q/Q +11.7%) and beats earnings estimates in 3 of the last 4 quarters, supporting its current valuation above the Graham Number of $141.93. Profit margins and ROA are solid for the banking sector, but missing data on key leverage and liquidity ratios, along with insider selling, raise caution. The stock trades near analyst target ($134.30) with mixed technicals and low insider sentiment, warranting a cautious hold despite attractive yield and growth.

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 2/9 and a massive valuation gap where the current price ($47.93) trades at a significant premium to the Graham Number ($8.34) and Intrinsic Value ($6.23). While long-term price performance has been exceptional, current fundamentals show severe deterioration, including a negative YoY revenue growth of 10% and a catastrophic earnings surprise trend (-149.13% over the last 4 quarters). The dividend is unsustainable with a payout ratio of 123.58%, suggesting capital erosion. Despite bullish analyst targets, the hard data indicates a high-risk, overvalued asset.